Keyphrases
Therapeutic Drug Monitoring
86%
Polymorphism
61%
Cytochrome P450 2D6 (CYP2D6)
55%
Antipsychotics
38%
Pharmacogenetics
34%
Psychiatry
32%
Drug Therapy
32%
Weight Gain
32%
Neuropsychopharmacology
31%
Consensus Guidelines
31%
Pharmacotherapy
28%
Pharmacogenetic Testing
27%
Antipsychotic-induced Weight Gain
25%
Digoxin
25%
Pharmacokinetics
24%
CYP2D6 Genotype
22%
Olanzapine
21%
CYP2C19
20%
Amitriptyline
20%
Cyclosporine
19%
Second-generation Antipsychotics
19%
Clinical Practice
18%
Serum Concentration
18%
Antidepressants
18%
Cytochrome P450 1A2 (CYP1A2)
18%
Genotype
17%
Monitoring Task
15%
Drug Concentration
15%
LightCycler
15%
Psychiatric Inpatients
14%
Antidepressant Therapy
14%
Intermediate Metabolizers
14%
Schizophrenia
13%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
13%
Blood Samples
13%
Drug Monitoring
13%
Metabolism
12%
Kidney Transplant Recipients
12%
Genetic Basis
12%
Rs17782313
12%
Molecular Diagnostics
12%
Nortriptyline
12%
Mycophenolic Acid
12%
Canrenone
12%
Mycophenolate
12%
Molecular Brain Imaging
12%
Imaging Tests
12%
Tricyclic Antidepressants
12%
Digoxin Toxicity
11%
Therapeutic Agents
10%
Pharmacology, Toxicology and Pharmaceutical Science
Therapeutic Drug Monitoring
100%
Pharmacotherapy
59%
Pharmacogenetics
50%
Pharmacokinetics
43%
Side Effect
40%
Psychopharmacology
37%
Antipsychotic
31%
Typical Antipsychotic
27%
Antidepressant
26%
CYP2D6
25%
Psychotropic Agent
25%
Digoxin
25%
Toxic Injury
20%
Olanzapine
20%
Mycophenolic Acid
18%
Amitriptyline
14%
CYP2C19
14%
Drug Concentration
14%
Serotonin Transporter
13%
Ciclosporin
13%
Canrenone
12%
Rivastigmine
12%
Tricyclic Antidepressant
11%
Donepezil
11%
Adverse Event
11%
Pharmacodynamics
11%
Digoxin Toxicity
11%
Spironolactone
9%
Hemodialysis
9%
Immunosuppressive Agent
9%
Depression
8%
Drug Metabolizing Enzyme
8%
High Performance Liquid Chromatography
8%
CYP1A2
8%
Selective Serotonin Reuptake Inhibitor
8%
Cholinesterase Inhibitor
7%
Tolerability
7%
Calcineurin Inhibitor
7%
Normal Human
7%
Immunoassay
7%
Disease
7%
Clozapine
7%
Toxicity
7%
Glucuronide
6%
Peroxisome Proliferator Activated Receptor Gamma
6%
Gastrointestinal Symptom
6%
Paroxetine
6%
Inosinate Dehydrogenase
6%
Organic Cation Transporter
6%
Fatty Acid
6%
Neuroscience
Antipsychotic
45%
Pharmacokinetics
39%
Psychiatry
37%
Cytochrome P450 2D6
31%
Psychopharmacology
31%
Typical Antipsychotic
30%
Olanzapine
23%
Blood Plasma
18%
Cytochrome P450 1A2
18%
Receptor
17%
Metabolic Pathway
16%
Gene Dosage
15%
Antidepressant
15%
Intellectual Disability
15%
Amitriptyline
14%
Antidepressant Therapy
14%
Cytochrome P450 2C19
14%
Serotonin Transporter
14%
Variable Number Tandem Repeat
13%
Adverse Effect
12%
Serotonergic
12%
Psychoactive Drug
12%
Rivastigmine
12%
Tricyclic Antidepressant
12%
Donepezil
11%
Real-Time Polymerase Chain Reaction
11%
Nortriptyline
10%
Clozapine
10%
Receptor Gene
9%
Selective Serotonin Reuptake Inhibitor
9%
Cytochrome
8%
Acetylcholinesterase Inhibitor
7%
Depression
7%
Melanocortin 4 Receptor
7%
Amisulpride
7%
Calcineurin
7%
Genetic Polymorphism
7%
Ciclosporin
6%
Tacrolimus
6%
5-HT2C Receptor
6%
Inosine-5′-monophosphate dehydrogenase
6%
Melanocortin
6%
Peroxisome Proliferator-Activated Receptor Gamma
6%
Paroxetine
6%
Organic Cation Transporter 1
6%
Drug Metabolizing Enzyme
6%
Organic Cation Transporter
6%
Doxepin
6%
Brain Imaging
6%
Spironolactone
6%
